Search

everythinglearnresearchcommunity

for

Search:↓

The combination of the excimer lamp and liquor carbonis detergens is more effective for scalp psoriasis than the lamp alone.

JAK/STAT inhibitors show promise for skin diseases but aren't yet approved.

Combining imiquimod with diphenylcyclopropenone may improve treatment outcomes for alopecia areata patients who don't respond to diphenylcyclopropenone alone.

JAK inhibitors effectively treat skin conditions and topical forms are safer.

A woman with bullous pemphigoid had an allergic reaction to azathioprine, but got better with alternative treatments.

Dupilumab can help regrow hair and improve skin conditions in patients with severe atopic dermatitis and alopecia areata.

Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.

An 84-year-old man got a rare scalp condition from using imiquimod cream, which was cured with systemic steroids.

A woman with severe hair loss was successfully treated with the drug adalimumab.

Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.

The combination therapy is safe and more effective for treating pediatric facial and cervical vitiligo.

Blocking certain proteins can significantly regrow hair in severe alopecia areata.

Rituximab may cause skin issues, but baricitinib can help improve them.

Janus kinase inhibitors show promise in treating autoimmune skin diseases.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

A man had a rare skin reaction from a hair loss medication, which improved after stopping the drug.

Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.

Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.

JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.

Adding dupilumab led to almost complete hair regrowth in a patient with alopecia areata who only partially responded to baricitinib.

OR101 may effectively treat atopic dermatitis and similar skin conditions.

Deuruxolitinib is FDA-approved for treating severe alopecia areata.

Significant progress was made in understanding PXE, but effective treatments are still needed.

Tofacitinib effectively treated severe alopecia areata in a 14-year-old girl.

Adipose stem cell exosomes can effectively reduce facial redness and improve skin health in atopic dermatitis patients.

Apremilast did not work for treating severe alopecia areata.

Biologics show promise in treating various stubborn skin diseases, but more research and better reimbursement criteria are needed.